421 related articles for article (PubMed ID: 26842387)
1. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.
Chasen MR; Rapoport BL
Future Oncol; 2016 Mar; 12(6):763-78. PubMed ID: 26842387
[TBL] [Abstract][Full Text] [Related]
2. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
[TBL] [Abstract][Full Text] [Related]
3. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2015; 15(10):1127-33. PubMed ID: 26366937
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
Rojas C; Slusher BS
Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
[TBL] [Abstract][Full Text] [Related]
5. Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy.
Rapoport B; van Eeden R; Smit T
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):17-29. PubMed ID: 27894202
[TBL] [Abstract][Full Text] [Related]
6. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
Rapoport BL; Aapro M; Chasen MR; Jordan K; Navari RM; Schnadig I; Schwartzberg L
Drug Des Devel Ther; 2017; 11():2621-2629. PubMed ID: 28919712
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
Hesketh PJ; Schnadig ID; Schwartzberg LS; Modiano MR; Jordan K; Arora S; Powers D; Aapro M
Cancer; 2016 Aug; 122(15):2418-25. PubMed ID: 27176138
[TBL] [Abstract][Full Text] [Related]
8. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Rapoport B; Chua D; Poma A; Arora S; Wang Y; Fein LE
Support Care Cancer; 2015 Nov; 23(11):3281-8. PubMed ID: 25940030
[TBL] [Abstract][Full Text] [Related]
9. Rolapitant: a pooled analysis of its efficacy and safety in the prophylaxis of chemotherapy-induced nausea and vomiting.
Abdel-Rahman O; Fouad M
Future Oncol; 2016 Mar; 12(6):871-9. PubMed ID: 26806790
[TBL] [Abstract][Full Text] [Related]
10. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
12. The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy.
Navari RM
Expert Opin Drug Saf; 2019 Dec; 18(12):1127-1132. PubMed ID: 31622113
[No Abstract] [Full Text] [Related]
13. Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting.
Ahmed H; Hammad AM; Abushouk AI; Zidan M; Salem M; Negida A; Abdel-Daim MM
Curr Probl Cancer; 2018; 42(2):241-255. PubMed ID: 29310827
[TBL] [Abstract][Full Text] [Related]
14. Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomiting.
Navari R
Drugs Today (Barc); 2016 Aug; 52(8):431-438. PubMed ID: 27722211
[TBL] [Abstract][Full Text] [Related]
15. Rolapitant: An NK-1 Receptor Antagonist for the Prevention of Chemotherapy- Induced Nausea and Vomiting.
Rapoport BL
Rev Recent Clin Trials; 2017; 12(3):193-201. PubMed ID: 28393710
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
18. Rolapitant: A Review in Chemotherapy-Induced Nausea and Vomiting.
Heo YA; Deeks ED
Drugs; 2017 Oct; 77(15):1687-1694. PubMed ID: 28929404
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy.
Rapoport B; Smit T
Expert Opin Drug Saf; 2017 Jun; 16(6):697-710. PubMed ID: 28460548
[TBL] [Abstract][Full Text] [Related]
20. Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV).
Rashad N; Abdel-Rahman O
Drug Des Devel Ther; 2017; 11():947-954. PubMed ID: 28392676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
